Yifan Pharmaceutical Co., Ltd. engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally. It offers oral slow controlled release preparations, micron suspensions, micelles for injection, and liquid preparations. The company also focuses on hematologic maliganancies, inflammatory, endocrinology/metabolic, dermatological, gynecologic, and pediatric diseases, etc. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Hangzhou, China.
Metrics to compare | 002019 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship002019PeersSector | |
---|---|---|---|---|
P/E Ratio | 46.4x | 32.9x | −0.5x | |
PEG Ratio | 0.25 | −0.17 | 0.00 | |
Price/Book | 2.1x | 3.3x | 2.6x | |
Price / LTM Sales | 3.5x | 5.4x | 3.2x | |
Upside (Analyst Target) | 13.3% | 14.4% | 45.7% | |
Fair Value Upside | Unlock | 1.3% | 8.6% | Unlock |